SAN FRANCISCO, Oct. 23 - Illumina today reported increased revenue for the third quarter of 2002.
The company said its total revenue was $3 million in the third quarter which ended September 29, up from $700,000 in the same quarter of 2001. Strong oligo sales and first material revenue for genotyping services contributed to the rise in revenue, according to the company.
Illumina reported a net loss of $7.6 million, or $.24 per share, in the third quarter 2002 compared to a net loss of $5.8 million, or $.19 per share, in the year-ago period.
R&D spending increased to $6.4 million compared to $5.2 million in the same period a year ago.
Illumina also reported $73.7 million in cash and investments at the end of September 2002.
Click here for more information.